Loading chart…
PRE-MARKET
Glenmark Pharmaceuticals Limited, together with its subsidiaries, research, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides various products in the therapeutic areas of dermatology, respiratory, oncology, cardiology, diabetes, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, and respiratory-metered dose inhaler, dry powder inhaler, and nasal sprays.
Glenmark Pharmaceuticals Limited (GLENMARK) is listed on the NSE in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry. The GLENMARK share price is ₹2,594.90 (+4.56% today), with a market capitalisation of ₹732B and a price-to-earnings (P/E) ratio of 50.5. MarketRipple tracks the GLENMARK investment thesis, the ripple-chain impact of market events on Glenmark Pharmaceuticals Limited, and the Healthcare sector outlook.
Open
₹2,600.00
High
₹2,618.10
Low
₹2,572.50
Prev. Close
₹2,481.80
52W High
₹2,682.50
52W Low
₹1,807.00
Day range
₹2,572.50–₹2,618.10
52-week range
₹1,807.00–₹2,682.50
Volume
112K
P/E
50.5
ROE
14.0%
D/E
0.06
Margin
9.2%
Glenmark Pharmaceuticals Limited (NSE: GLENMARK) is currently trading at ₹2,594.90 (+4.56%).
Glenmark Pharmaceuticals Limited's market capitalization is ₹732B.
Glenmark Pharmaceuticals Limited's price-to-earnings (P/E) ratio is 50.5.
Glenmark Pharmaceuticals Limited operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic).
Analyst consensus on Glenmark Pharmaceuticals Limited currently reads neutral, based on 11 analysts covering the stock. This is third-party analyst data, not a MarketRipple recommendation.